Structural and informational barriers drive nonrepresentative trial cohorts; aligning enrollment with catchment demographics and collaborating across centers improves generalizability and equity.

Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...

In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, ...

Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling ...